Phase 2 pilot study of Pathfinders: a psychosocial intervention for cancer patients by Abernethy, Amy P. et al.
Phase 2 pilot study of Pathfinders: a psychosocial intervention
for cancer patients
Amy P. Abernethy,
Division of Medical Oncology, Department of Medicine, Duke University Medical Center (DUMC),
Box 3436, Durham, NC 27710, USA. Duke Comprehensive Cancer Center, DUMC, Box 2717,
Durham, NC, USA
James E. Herndon II,
Duke Comprehensive Cancer Center, DUMC, Box 2717, Durham, NC, USA. Department of
Biostatistics and Bioinformatics, DUMC, Durham, NC, USA
April Coan,
Duke Comprehensive Cancer Center, DUMC, Box 2717, Durham, NC, USA
Tina Staley,
Division of Medical Oncology, Department of Medicine, Duke University Medical Center (DUMC),
Box 3436, Durham, NC 27710, USA
Jane L. Wheeler,
Division of Medical Oncology, Department of Medicine, Duke University Medical Center (DUMC),
Box 3436, Durham, NC 27710, USA
Krista Rowe,
Division of Medical Oncology, Department of Medicine, Duke University Medical Center (DUMC),
Box 3436, Durham, NC 27710, USA
Sophia K. Smith, and
Duke Comprehensive Cancer Center, DUMC, Box 2717, Durham, NC, USA. Department of
Health Policy and Management, University of North Carolina, Box 7411, Chapel Hill, NC, USA
H. Kim Lyerly
Duke Comprehensive Cancer Center, DUMC, Box 2717, Durham, NC, USA. Department of
Surgery, DUMC, Box 2714, Durham, NC, USA
Amy P. Abernethy: amy.abernethy@duke.edu
Abstract
Purpose—Pathfinders is a multi-faceted psychosocial care program for cancer patients; it was
developed in community oncology and adapted to the academic oncology setting. This
prospective, single-arm, phase 2 pilot study examined the acceptability and feasibility of
Pathfinders for women with metastatic breast cancer.
Methods—Over 3 months, participants completed patient-reported surveys including the Patient
Care Monitor (PCM, review of systems), Functional Assessment of Chronic Illness Therapy—
Breast Cancer (FACT-B), Self Efficacy, and a single-item survey asking patients whether the
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program was helpful to them. A technology-based data collection system was used to capture
electronic patient-reported outcomes at point of care, report symptoms in real time to clinicians,
and collect warehouse data to provide a detailed longitudinal picture of the patient experience
when receiving Pathfinders.
Results—Participants (n=50) were: mean age 51 (SD 11); 76% white, 20% black; 74% married;
50% college degree. Forty-two (n=42) patients completed baseline and 3-month assessments.
Statistically significant improvements (all P<0.05) occurred in PCM subscales for Distress (mean
[SE]=−3.42 [1.21]), Despair (−4.53 [1.56]), and Quality of Life (2.88 [0.97]), and the FACT-B
Emotional Wellbeing subscale (2.07 [0.46]). Of the 29 participants asked if Pathfinders was
helpful, 27 (93%) responded positively and two did not respond. Other instruments measuring
symptoms, quality of life, and self-efficacy showed improvement.
Conclusions—In a phase 2 pilot study, Pathfinders was helpful to patients and is feasible in an
academic medical center. Follow-up data collected at the 3-month assessment suggest that the
program impacts various psychological outcomes, notably distress and despair.
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Introduction
A substantial evidence base confirms that cancer patients experience significant
psychosocial symptoms. Psychological distress, including anxiety, depression, and changes
in mood, affects over 35% of all patients with cancer [1]. For example, studies have found
that depression diminishes cancer patients’ quality of life (QOL), and that greater severity of
depression is associated with a faster rate of disease progression and a greater severity of
other cancer-related symptoms, particularly pain [2, 3]. In addition, studies of cancer
patients meeting criteria for post-traumatic stress symptomatology have been also
documented, though incidence rates vary [4].
Currently, the primary mode of delivering psychosocial care to cancer patients is through
adjunctive programs (e.g., psychotherapy, support groups, and psycho-education). These
services are typically provided by social workers, counselors, and chaplains in parallel with
medical care, but with providers often uninformed. Patient navigator models attempt to
bridge communications between the patient, family, and medical team; however, it is
difficult to determine the benefits given their diversity in content. Likewise, limited rigorous
research has been conducted on cancer patient support programs for reasons including lack
of resources, inter-program variability, and difficulty identifying key outcome variables.
Specific psychological interventions such as cognitive-behavioral therapy and psycho-
education (e.g., self-care information provided to patients post-surgery) have been studied in
adult cancer patients and survivors. Several meta-analyses have looked at the effectiveness
of these interventions but results have been varied, igniting a debate over their effectiveness
[5, 6]. A review of the literature in June 2008 yielded no rigorous studies on any
comprehensive psychosocial intervention that was fully integrated into the context of
medical care.
Pathfinders is a psychosocial program designed for cancer patients at all disease stages. As
shown in Fig. 1, the program seeks to effect “personal recovery” by identification and
activation of the individual’s innate strengths through both therapist-led and self-guided
inquiry.
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A manual guides the implementation, but the intervention is tailored to address patient-
specific needs. Pathfinders work in close concert with clinical providers to facilitate patient/
provider communication and attend to their patients’ non-medical needs. The program has
served patients at two community sites in Colorado since 2000 and at an academic medical
center in North Carolina since 2006.
This paper presents the initial results of a pilot study (i.e., phase 2 clinical trial) of
Pathfinders among metastatic breast cancer patients at Duke University Medical Center,
which was conducted in parallel with program implementation. The purpose of the pilot was
to determine whether this model of psychosocial care is acceptable to patients and feasible
in the academic medical center setting. A further objective was to determine the best




This was a prospective, single-arm, phase 2 pilot study conducted at one institution (Duke
University Medical Center, Durham, NC, USA) from January 2006 to June 2008.
Participants received the Pathfinders intervention over a 6-month period, interfacing with a
Pathfinder at baseline and approximately monthly thereafter. The primary outcome was
acceptability, assessed by the proportion of patients reporting that the program helped them.
Secondary outcomes included QOL, distress, despair, functionality, spirituality, fatigue, self-
efficacy, and symptoms. A 3-month analysis was planned to determine if the study should
continue and to direct research next steps; results are presented here. The Duke Institutional
Review Board approved the study, and informed consent was obtained from all study
participants.
The study was designed to ensure that the Pathfinders intervention could be delivered as
seamlessly as possible (i.e., with little intrusion from the research team). Data were collected
in a clinic using paper-based and electronic versions of validated assessments; electronic
surveys were delivered by e/Tablet (wireless, tablet-style, personal computers used in the
clinical waiting area), an efficient and unobtrusive system coordinated as a part of the
normal clinical care environment [7].
Participants and setting
The original protocol stipulated enrollment of 48 eligible patients to ensure that at least 40
patients would complete at least the 3-month assessment. A sample size of 40 provided
>80% power to differentiate between a helpfulness rate of 80% and 95% at the 3-month
assessment with a one-sample binomial test (P=0.05). Due to higher-than-anticipated
attrition, the sample size goal was raised to 55 patients.
Eligible participants were: adult; female; diagnosed with metastatic breast cancer; receiving
chemotherapy, intravenous immunotherapy, or intravenous bisphosphonate therapy;
expected to live ≥6 months; able/willing to travel to clinic at least every 4 weeks; English-
literate; and consenting.
Intervention
Each patient met individually with a “Pathfinder”, a trained and licensed social worker.
Psychosocial services provided by the Pathfinder included cognitive restructuring, mind/
body technique instruction, and self-care and end-of-life planning. While following a
standardized program manual, the Pathfinder customized the intervention to the specific
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circumstances, needs, and characteristics of the individual patient. It was intended that these
newly developed and enhanced skills would help patients navigate through potential
setbacks of cancer and its treatment and maintain personal well-being through survivorship
or end of life. The Pathfinder met with the participant at least monthly for up to 6 months
and communicated regularly with the oncology team.
Data collection and instruments
Patient-reported outcomes were collected electronically (via e/Tablets [7]) and using paper-
based surveys. Electronic instruments included: (1) Functional Assessment of Cancer
Therapy—Breast Cancer Scale (FACT-B) [8, 9], a 44-item self- report instrument,
measuring QOL in breast cancer patients; (2) Functional Assessment of Chronic Illness
Therapy—Fatigue Scale (FACIT-F) [10], a 13-item survey, measuring fatigue; (3) M.D.
Anderson Symptom Inventory (MDASI) [11], a 19-item survey with two subscales,
measuring severity of symptoms and their interference with daily living; and (4) Patient
Care Monitor 2™ (PCM, originally called Cancer Care Monitor; Supportive Oncology
Services, Inc.) [12], an 86-item review of systems, generating seven subscales including a
global QOL score.
Paper-based surveys included: (1) the helpfulness question; (2) Self Efficacy Scale [13]; (3)
FACIT—Spiritual Well-Being Scale (FACIT-Sp) [14]; (4) Life Orientation Test—Revised
[15]; and (5) Brief COPE Survey [16].
Statistical analysis
Statistical analyses focused on data collected between baseline and 3-month assessments.
The primary foci were the (1) acceptability and feasibility of Pathfinders at an academic
medical center and (2) strength of other outcomes as potential endpoints for a larger study of
this psychosocial model. Feasibility and acceptability was assessed through the helpfulness
question and estimated with an exact 95% binomial confidence interval. A paired t test was
used to assess changes in subscale scores between baseline and the 3-month assessment with
a step-down Bonferroni approach to adjust significance levels given the multiple analyses.
Among study participants completing baseline and 3-month assessments, the proportion of
participants with a score >3 was reported for individual symptoms (PCM) at baseline and 3
months. For symptoms that improved by >10%, McNemar’s test was used to determine if
there were differences in the proportion of patients with a symptom score >3 at baseline and
at 3 months. Bonferroni corrections were used to adjust significance levels. All analyses
were conducted using SAS Version 9.1. A two-sided significance level of 0.05 was used for
all statistical tests.
Results
Participants (n=50) were: mean age 51 (SD, 12); 76% white, 20% black; 74% married; 50%
college degree (Table 1). The study population had advanced breast cancer; attrition at 3
months was 16% (four died, one withdrew, and three did not have assessment data available
due to rapidly progressive illness). Of participants completing the 3-month assessment
(n=42), 29 (69%) were asked the Pathfinders helpfulness question due to difficulties with
administration of paper surveys, and of those, 27 (93%) indicated that Pathfinders was
helpful and two did not respond.
As shown in Table 2, significant improvements (all P<0.05) in QOL and distress scores
from baseline to 3 months were achieved despite participants’ advanced and progressive
disease: PCM Distress (mean change [SE]= −3.42 [1.21]); PCM Despair (−4.53 [1.56]);
PCM Quality of Life (2.88 [0.97]); and FACT-G Emotional Wellbeing (2.07 [0.46]). While
Abernethy et al. Page 4













statistically non-significant, other measures (e.g., FACT-B, FACIT-F, and MDASI
Interference) showed a trend towards improvement. Finally, Table 3 highlights symptoms
that showed a >10% change in prevalence, with change in prevalence of nervousness
significant at P<0.05.
Discussion
This phase 2 pilot study examined the short-term impact of the Pathfinders program on
QOL-related outcomes. Before preparing for a randomized controlled trial, it was necessary
to determine whether the academic medical setting could accommodate this type of
psychosocial program or whether there was the potential for positive impact. Results
indicated that most (93%) study participants found the intervention helpful, and the high
retention rate coupled with continuous referrals from physicians affirmed the program’s
acceptability.
Certain outcomes (e.g., distress and despair) evidenced improvement despite the progress of
disease. Recent studies have examined trends in QOL-related scores in patients nearing end
of life. One prospective, longitudinal study in an advanced cancer cohort (n=67) reported
steady decline in FACT-G scores over the 6 months preceding death, accelerated decline in
the last 2–3 months, and dramatic increase in psychological symptoms in the last month
[17]. In contrast, a study among breast cancer survivors in China reported significant
improvement over time in many outcomes. However, even among these long-term
survivors, certain aspects of QOL either failed to improve or worsened (e.g., emotions and
social support) [18]. Because we lack survival data on our cohort, we were unable to directly
relate these results to our population; however, they demonstrate a pattern that suggests the
need for psychosocial intervention for advanced cancer patients nearing death.
Many participants experienced significant improvement in self-efficacy, which is defined as
having confidence to carry out a behavior necessary to reach a desired goal. Individuals with
high self-efficacy for health behaviors are more likely to exercise, seek preventive care, halt
negative behaviors (e.g., smoking), and report better health status [19, 20]. Given self-
efficacy’s potential function as a mediator of Pathfinders’ effect on outcomes, future
analyses will examine the correlation between improvement in various patient resources
(e.g., self-efficacy and coping) and QOL-related outcomes.
While its primary focus is on psychosocial outcomes, Pathfinders may contribute to
alleviation of other symptoms and side effects of cancer and cancer treatment. For example,
participants reported a >10% decrease in prevalence between baseline and 3 months on
fatigue. The mechanism of such changes is unclear, although likely relates to the close
relationship with psychological distress. Efforts to evaluate various inflammatory pathways
as a potential mechanism are also underway.
This study had several limitations, including the lack of a control group. This was intended
to be an exploratory phase 2 pilot study to establish feasibility and determine the potential
for meaningful outcomes; based upon these results, a phase 3 trial is planned. A second
limitation is that the pilot study included only women with metastatic breast cancer; hence,
results may not generalize to men or to other cancer diagnoses. Third, this pilot study relied
heavily on a single provider of the intervention (i.e., one Pathfinder), although three
additional Pathfinders have been trained over the course of the study. Finally, while an
attempt was made to ensure that study visits were timed per protocol, the realities of usual
clinical care for sick patients translated to visits that were frequently off-schedule.
Despite these limitations, data gained in this pilot study led to clarification of design
elements to be used in a randomized controlled trial that will rigorously test Pathfinders.
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Appropriate endpoints include distress and QOL measures; in addition, we are considering a
model in which self-efficacy functions as a mediator of the intervention’s effect. A
confirmatory trial will have a broader scope, enrolling four cancer types (breast, lung,
colorectal cancer, and ovarian) and both genders, which will help establish the
generalizability of results.
In this preliminary study, we found that Pathfinders, a novel and multi-faceted psychosocial
program, could be adapted to an academic center and was deemed helpful by patients with
metastatic breast cancer. Follow-up data collected at the 3-month assessment suggest that
the program impacts various psychological outcomes, notably distress and despair, and
provides justification for further study in a more diverse cancer sample.
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Conceptual model guiding the Pathfinders pilot study. Quantitative data on helpfulness,
quality of life, symptoms, psychological distress, self-efficacy, and spirituality are presented
here. Other information such as coping, self-care, exercise, nutrition, inflammation, and
health service utilization will be presented separately
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Table 1
Demographics of the study sample
Number or mean (SD) Percent or [range]
Gender
 Female 50 100%
Age in years
 At study enrollment 51.2 (11.5) [31–79]
 At diagnosis 47.3 (11.5) [26–79]
Marital status
 Married 37 74%
 Not married 13 26%
Education
 Less than bachelor’s degree 25 50%
 Bachelor’s degree and above 25 50%
Race/ethnicity
 White, Caucasian 38 76%
 Black or African-American 10 20%
 Korean 1 2%
 Other 1 2%
Cancer stage at diagnosis
 Stage 1 6 12%
 Stage 2 19 38%
 Stage 3 5 10%
 Stage 4 12 24%
 Missing 8 16%
Current extent of disease
 Distant metastases 50 100%
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Table 2
Change in subscale scores from baseline
Scale: subscale Number Baseline mean (SE)
Mean change from baseline mean
(SE), at 3 months
Meaning of direction of
changea
PCM: general physical symptoms 36 26.23 (2.59) −3.58 (1.84) Improvement
PCM: treatment side effects 36 12.5 (1.36) −0.92 (1.52)
PCM: distress 36 11.36 (1.82) −3.42 (1.21)* Improvement
PCM: despair 36 11.53 (2.68) −4.53 (1.56)* Improvement
PCM: impaired performance 30 12.73 (2.17) −1.03 (1.61) Improvement
PCM: impaired ambulation 35 4.49 (1.11) −1.31 (0.84) Improvement
PCM: quality of life 30 −13.52 (1.85) 2.88 (0.97)* Improvement
FACT-G: physical 36 16.99 (1.07) 1.73 (0.74) Improvement
FACT-G: social 34 20.72 (0.96) 0.3 (0.57)
FACT-G: emotional 36 15.56 (0.81) 2.07 (0.46)* Improvement
FACT-G: functional 35 15.34 (1.13) 0.07 (0.72)
FACT-B 40 22.81 (0.79) 1.69 (0.75) Improvement
FACIT-Fatigue 39 25.67 (1.93) 2.91 (1.19) Improvement
FACIT-Spirituality: meaning/peace 25 21.97 (1.61) 1.95 (0.99) Improvement
FACIT-Spirituality: faith 25 12.24 (0.84) −0.04 (0.57)
MDASI: symptom severity 41 2.67 (0.3) −0.17 (0.22)
MDASI: interference 41 3.67 (0.45) −0.73 (0.32) Improvement
Self Efficacy: other 25 58.04 (3.78) 4.23 (2.91) Improvement
Self Efficacy: pain 24 61.19 (4.85) 3.1 (4.22) Improvement
Self Efficacy: functioning 24 62.64 (4.76) 4.58 (3.88) Improvement
Self Efficacy: overall 24 59.18 (4.29) 3.94 (3.19) Improvement
Italics indicate statistically significant improvement
PCM Patient Care Monitor, FACT-G/-B Functional Assessment of Cancer Therapy—General/Breast, FACIT Functional Assessment of Chronic
Illness Therapy, MDASI M.D. Anderson Symptom Inventory, SE standard error
*
P<0.05 after step-down Bonferroni adjustment
a
Survey instruments may reflect improvement by increasing or decreasing scores. The implications of the change are presented here
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Table 3
Change in selected symptoms from baseline, as reported on the Patient Care Monitor Instrument
System Symptom Change from baseline at 3 months
N
Percent with score >3 at
baseline
Percent with score >3 at 3
months
Constitutional Weight loss 36 19 8
Weight gain 33 24 21
Fatigue (tiredness) 35 66 49
Endocrine Reduced sexual enjoyment, interest, or performance 34 41 29
Gastrointestinal Nausea (queasy feeling) 35 20 11
Decrease in appetite 36 17 6
Increase in appetite 35 9 9
Psychiatric Feeling I would be better off deada 36 8 3
Feeling hopelessa 36 22 11
Nervous, tense, anxiousb 36 47 22*
Feeling helpless 36 25 19
Lost interest in pleasurable activitiesa 36 25 14
Feeling guiltya 36 25 11
Lost interest in peoplea 36 14 11
Worryb 36 44 33
Crying/feeling like cryingb 36 28 17
Sad (depressed)b 36 33 17
Feeling worthlessa 36 22 3
Italics indicate meaningful improvement with >10% change
*
P<0.05 after step-down Bonferroni adjustment
a
Patient Care Monitor Despair subscale item
b
Patient Care Monitor Distress subscale item
Support Care Cancer. Author manuscript; available in PMC 2011 August 24.
